John Oyler - Jul 9, 2025 Form 4 Insider Report for BeOne Medicines Ltd. (ONC)

Signature
/s/ Qing Nian, as Attorney-in-Fact
Stock symbol
ONC
Transactions as of
Jul 9, 2025
Transactions value $
-$7,044,591
Form type
4
Date filed
7/11/2025, 05:14 PM
Previous filing
Jun 25, 2025
Next filing
Sep 18, 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
OYLER JOHN Chief Executive Officer, Director C/O BEONE MEDICINES I GMBH, AESCHENGRABEN 27, 21ST FLOOR, BASEL, SWITZERLAND /s/ Qing Nian, as Attorney-in-Fact 2025-07-11 0001042047

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ONC American Depositary Shares Sale -$1.69M -6.7K -24.11% $252.23 21.1K Jul 9, 2025 Direct F6, F7, F8
transaction ONC American Depositary Shares Sale -$2.35M -9.29K -44.04% $253.18 11.8K Jul 9, 2025 Direct F6, F7, F9
transaction ONC American Depositary Shares Sale -$2.61M -10.3K -86.85% $254.10 1.55K Jul 9, 2025 Direct F6, F7, F10
transaction ONC American Depositary Shares Sale -$396K -1.55K -100% $254.83 0 Jul 9, 2025 Direct F6, F7, F11
holding ONC Ordinary Shares 7.81M Jul 9, 2025 Direct
holding ONC Ordinary Shares 482K Jul 9, 2025 See Footnote F1
holding ONC Ordinary Shares 7.72M Jul 9, 2025 See Footnote F2
holding ONC Ordinary Shares 28.2M Jul 9, 2025 See Footnote F3
holding ONC Ordinary Shares 9.55M Jul 9, 2025 See Footnote F4
holding ONC Ordinary Shares 102K Jul 9, 2025 See Footnote F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 These securities are held by the P&O Trust, the beneficiaries of which include the Reporting Person's child and others, for which the Reporting Person disclaims beneficial ownership.
F2 These securities are held in a grantor retained annuity trust, of which the Reporting Person's father is a trustee, for which the Reporting Person disclaims beneficial ownership.
F3 These securities are held by Oyler Investment LLC, of which 99% of the the limited liability company interest owned by a grantor retain annuity trust, of which the Reporting Person's father is a trustee, for which the Reporting Person disclaims beneficial ownership.
F4 These securities are held for the benefit of the Reporting Person in a Roth IRA PENSCO trust account.
F5 These securities are held by The John Oyler Legacy Trust for the benefit of the Reporting Person's minor child, for which the Reporting Person disclaims beneficial ownership.
F6 Each American Depositary Share represents 13 Ordinary Shares
F7 The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2025.
F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $251.63 to $252.61, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $252.63 to $253.62, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $253.63 to $254.62, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $254.63 to $255.08, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.